Revenio Group
REG1V.HE Small CapHealthcare · Medical Devices
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Revenio Group en bref
Revenio Group (REG1V.HE) is currently trading at 12,22 € with a market capitalization of 308 M €. The trailing P/E ratio stands at 20.71x, with a forward P/E of 12.58x. The 52-week range spans from 11,86 € to 26,35 €; the current price is 53.6% below the yearly high. Year-over-year revenue growth stands at +4.6%. The net profit margin stands at 14.15%.
💰 Dividende
Revenio Group pays an annual dividend of 0,40 € per share, representing a yield of 3.27%. The payout ratio stands at 67.85%.
📊 Avis des analystes
4 analystes évaluent Revenio Group (REG1V.HE) au consensus : None. L'objectif de cours moyen est de 19,38 €, soit un potentiel de +58.55% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,00 € à 23,50 €.
Revenio Group : la thèse d'investissement en détail
Revenio Group (REG1V.HE) operates in the Healthcare — specifically Medical Devices — and is headquartered in Finland. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 69.94%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Revenue growth has slowed to just 4.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy.
Valorisation en contexte
At a PEG of 6.37, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.
À surveiller
- The forward P/E of 12.58x is meaningfully below the trailing 20.71x — analysts expect earnings to step up; the next earnings release is the test.
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The dividend yield near 3.27% combined with a payout ratio of 67.85% leaves room for further hikes — a track record of consecutive raises is a strong income signal.
- The analyst consensus price target implies 58.55% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 69.94% — signe d'un pouvoir de fixation des prix
- Rendement du dividende solide de 3.27%
- Bilan solide avec faible endettement (D/E 9.21)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Revenio Group?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
